Dr. Margaret Hahn is a Clinician Scientist in the Schizophrenia Division at CAMH, and an Assistant Professor of Psychiatry at the University of Toronto. In December 2012, she completed a PhD at the Institute of Medical Sciences at the University of Toronto, which focused on metabolic-perturbations related to anti-psychotic medications.
Areas of Research
Dr. Hahn's research interests lie in translational work focused on the complex interplay between illness, antipsychotic treatments and cardiometabolic risk. Given the early accrual of metabolic risk leading to a 20% reduction in life expectancy for patients with schizophrenia, she has an interest in early episode individuals and prevention strategies. She currently co-leads the Mental Health and Metabolic Clinic at the CAMH within the Complex Mental Illness Program which specializes in metabolic monitoring and interventions for metabolic risk factors in individuals with serious mental illness.
View Dr. Hahn's publications on PubMed.